Federated Hermes
LEGN icon

Federated Hermes’s Legend Biotech LEGN Stock Holding History

Federated Hermes’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Sell
7,500
-20,500
-73% -$553K ﹤0.01% 1511
2026
Q1 		$507K Buy
28,000
+11,500
+70% +$219K ﹤0.01% 1289
2025
Q4 		$359K Sell
16,500
-1,048,803
-98% -$30M ﹤0.01% 1394
2025
Q3 		$34.7M Buy
1,065,303
+1,579
+0.1% +$58.3K 0.06% 334
2025
Q2 		$37.8M Sell
1,063,724
-327,947
-24% -$10.6M 0.07% 307
2025
Q1 		$47.2M Sell
1,391,671
-98,629
-7% -$3.54M 0.1% 246
2024
Q4 		$48.5M Sell
1,490,300
-49,400
-3% -$2.05M 0.11% 238
2024
Q3 		$75M Sell
1,539,700
-1,645
-0.1% -$87.6K 0.16% 164
2024
Q2 		$68.3M Buy
1,541,345
+4,285
+0.3% +$198K 0.16% 169
2024
Q1 		$86.2M Sell
1,537,060
-188,912
-11% -$11.4M 0.2% 134
2023
Q4 		$104M Sell
1,725,972
-38,524
-2% -$2.44M 0.26% 93
2023
Q3 		$119M Sell
1,764,496
-177,020
-9% -$12.3M 0.32% 68
2023
Q2 		$134M Sell
1,941,516
-397,284
-17% -$26M 0.33% 60
2023
Q1 		$113M Hold
2,338,800
– – 0.28% 75
2022
Q4 		$117M Hold
2,338,800
– – 0.32% 59
2022
Q3 		$95.4M Buy
2,338,800
+225,000
+11% +$10.6M 0.28% 76
2022
Q2 		$116M Buy
2,113,800
+905
+0% +$38.2K 0.32% 71
2022
Q1 		$76.8M Buy
2,112,895
+95,060
+5% +$3.76M 0.17% 160
2021
Q4 		$94.1M Buy
2,017,835
+250,000
+14% +$12.7M 0.17% 165
2021
Q3 		$89.4M Sell
1,767,835
-245,404
-12% -$10.2M 0.17% 164
2021
Q2 		$82.6M Sell
2,013,239
-92,339
-4% -$3.14M 0.15% 181
2021
Q1 		$61.1M Buy
2,105,578
+253,978
+14% +$6.93M 0.12% 225
2020
Q4 		$52.1M Buy
1,851,600
+783,383
+73% +$22.5M 0.11% 242
2020
Q3 		$33M Buy
1,068,217
+904,345
+552% +$30.4M 0.08% 290
2020
Q2 		$6.97M Buy
+163,872
New +$6.4M 0.02% 626

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Federated Hermes's LEGN Position: Q2 2026 in Review

Federated Hermes reduced its Legend Biotech (LEGN) stake by 73% in Q2 2026, selling an estimated $553K and leaving 7,500 shares worth $217K. The position accounts for ﹤0.01% of the portfolio, ranked #1511.

Federated Hermes first reported a position in LEGN in Q2 2020 and has held it in 25 quarters since. The position peaked at $134M in Q2 2023. 218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Federated Hermes held 7,500 shares of Legend Biotech worth $217K as of Q2 2026.
  • Federated Hermes sold 20,500 Legend Biotech shares in Q2 2026, an estimated $553K.
  • Legend Biotech made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1511 holding.
  • Federated Hermes first reported a position in Legend Biotech in Q2 2020 and has held it in 25 quarters since.
  • Federated Hermes's Legend Biotech position peaked at $134M in Q2 2023.
  • 218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.